References

• Barker, G. C. (2013). Analysis of Research Publications that Relate to Bioterrorism and Risk Assessment. Biosecurity and bioterrorism: biodefense strategy, practice, and science, 11(S1), S124-S133.
• Bouzianas, D. G. (2009). Medical countermeasures to protect humans from anthrax bioterrorism. Trends in microbiology, 17(11), 522-528.
• Dato, V., Wagner, M., Allswede, M., Aryel, R., & Fapohunda, A. (2001). The nation's current capacity for the early detection of public health threats including bioterrorism. Washington, DC: Agency for Healthcare Research and Quality.
• Dimitrov, N. B., Goll, S., Hupert, N., Pourbohloul, B., & Meyers, L. A. (2011). Optimizing tactics for use of the US antiviral strategic national stockpile for pandemic influenza. PLoS One, 6(1), e16094.
• Emory, A., & Light, F. (2005). EPA needs to fulfill its designated responsibilities to ensure effective BioWatch program. Environmental Protection Agency Evaluation Report(2005-P), 00012.
• Jernigan, D. B., Raghunathan, P. L., Bell, B. P., Brechner, R., Bresnitz, E. A., Butler, J. C., . . . Fischer, M. (2002). Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerging infectious diseases, 8(10), 1019.
• Kortepeter, M. G., Pavlin, J. A., Gaydos, J. C., & Rowe, J. R. (2000). Surveillance at US military installations for bioterrorist and emerging infectious disease threats. Military medicine, 165(8), ii.
• Larsen, J. C., & Disbrow, G. L. (2017). Project BioShield and the biomedical advanced research development authority: a 10-year progress report on meeting us preparedness objectives for threat agents. Clinical Infectious Diseases, 64(10), 1430-1434.
• Maddox, P. (2001). Bioterrorism: a renewed public health threat. MedSurg Nursing, 10(6), 333.
• Maher, C., & Lushniak, B. (2009). Availability of Medical Countermeasures for Bioterrorism Events: US Legal and Regulatory Options. Clinical Pharmacology & Therapeutics, 85(6), 669-671.
• Mellehovitch, V. B. (2004). Bioterrorism and Public Health: Nova Publishers.
• Noji, E. K. (2001). Bioterrorism: a ‘new'global environmental health threat. Global Change and Human Health, 2(1), 46.
• PILAT, J. (2000). The Bioterrorism Threat: Technological and Political Considerations: Los Alamos National Lab., NM (US).
• Preparedness, B. (2002). Public health security and bioterrorism preparedness and response act of 2002. Public law, 107(188), 188.
• Sleet, D., Bonzo, S., & Branche, C. (1998). An overview of the national center for injury prevention and control at the centers for disease control and prevention. Injury Prevention, 4(4), 308-312.
• Smith III, F. L. (2016). Malware and Disease: Lessons from Cyber Intelligence for Public Health Surveillance. Health security, 14(5), 305-314.
• Thacker, S. B., Qualters, J. R., Lee, L. M., Control, C. f. D., & Prevention. (2012). Public health surveillance in the United States: evolution and challenges. MMWR Surveill Summ, 61(Suppl), 3-9.
• Thacker, S. B., & Stroup, D. F. (2013). Origins and progress in surveillance systems. Infectious disease surveillance, 21-31.
• TO, F. (2001). Proliferation: Threat and Response.
• Valdivia-Granda, W. A. (2013). Biosurveillance enterprise for operational awareness, a genomic-based approach for tracking pathogen virulence. Virulence, 4(8), 745-751.
• Wynia, M. K., & Gostin, L. O. (2004). Ethical challenges in preparing for bioterrorism: barriers within the health care system. American Journal of Public Health, 94(7), 1096-1102.